{"id":"clobetasol-propionate-methotrexate","safety":{"commonSideEffects":[{"rate":"null","effect":"Skin atrophy"},{"rate":"null","effect":"Hypersensitivity reactions"},{"rate":"null","effect":"Gastrointestinal disturbances"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Clobetasol propionate works by binding to glucocorticoid receptors, which then inhibit the production of pro-inflammatory cytokines. Methotrexate, on the other hand, inhibits dihydrofolate reductase, leading to a decrease in DNA synthesis and cell proliferation.","oneSentence":"Clobetasol propionate is a topical corticosteroid that reduces inflammation, while methotrexate is an immunosuppressant that inhibits cell growth and division.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:06:23.097Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe plaque psoriasis"},{"name":"Severe atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT06555497","phase":"EARLY_PHASE1","title":"Topical 1% Methotrexate Gel Versus Clobetasol Propionate in Patients With Psoriasis","status":"COMPLETED","sponsor":"Dr. Jose N. Rodriguez Memorial Hospital and Sanitarium","startDate":"2022-01-01","conditions":"Pilot Study, Psoriasis","enrollment":2},{"nctId":"NCT04649697","phase":"PHASE3","title":"Rebamipide (Regular & Nanoparticulated) vs. Clobetasol in Management of Methotrexate-Induced Oral Ulceration in Rheumatoid Arthritis Patients","status":"UNKNOWN","sponsor":"Cairo University","startDate":"2020-12-01","conditions":"Rheumatoid Arthritis","enrollment":39},{"nctId":"NCT02313870","phase":"PHASE3","title":"Topical Steroids Alone or Associated With Methotrexate in Bullous Pemphigoid","status":"COMPLETED","sponsor":"University Hospital, Montpellier","startDate":"2008-01-22","conditions":"Bullous Pemphigoid","enrollment":322}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":39,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"clobetasol propionate + Methotrexate","genericName":"clobetasol propionate + Methotrexate","companyName":"University Hospital, Montpellier","companyId":"university-hospital-montpellier","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Clobetasol propionate is a topical corticosteroid that reduces inflammation, while methotrexate is an immunosuppressant that inhibits cell growth and division. Used for Severe plaque psoriasis, Severe atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}